PTI-125Dx is a blood-based biomarker/diagnostic candidate to detect Alzheimer’s disease.
PTI-125Dx is our blood-based diagnostic to detect Alzheimer’s disease.
The goal of PTI-125Dx is to make the detection of Alzheimer’s disease as simple as getting a blood test, possibly years before the appearance of any overt clinical symptoms.
We are developing PTI-125Dx as a simple, accurate and quantitative blood-based diagnostic to detect and monitor Alzheimer's disease. If successful, we believe PTI-125Dx has potential to make obsolete many of the current approaches for diagnosing Alzheimer’s disease.
In blinded studies, our investigational diagnostic, PTI-125Dx, detected >10-fold differences between patients with Alzheimer’s and age-matched normal controls or young cognitively intact subjects (N=232).
This clinical-stage program is funded by NIH as well.